Acromegaly - Pipeline Review, H1 2020

March 2020 | 103 pages | ID: A268033C2C7EN
Global Markets Direct

Abstracts

Acromegaly - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Pipeline Review, H1 2020, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.

Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acromegaly - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 8, 6, 5 and 3 respectively.

Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Hormonal Disorders).
• The pipeline guide reviews pipeline therapeutics for Acromegaly (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Acromegaly (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Acromegaly (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Acromegaly (Hormonal Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Acromegaly - Overview
Acromegaly - Therapeutics Development
Acromegaly - Therapeutics Assessment
Acromegaly - Companies Involved in Therapeutics Development
Acromegaly - Drug Profiles
Acromegaly - Dormant Projects
Acromegaly - Discontinued Products
Acromegaly - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Acromegaly, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Acromegaly - Pipeline by Amryt Pharma Plc, H1 2020
Acromegaly - Pipeline by Antisense Therapeutics Ltd, H1 2020
Acromegaly - Pipeline by Aquestive Therapeutics Inc, H1 2020
Acromegaly - Pipeline by Ascil Proyectos SL, H1 2020
Acromegaly - Pipeline by Auritec Pharmaceuticals Inc, H1 2020
Acromegaly - Pipeline by Camurus AB, H1 2020
Acromegaly - Pipeline by Chiasma Inc, H1 2020
Acromegaly - Pipeline by Crinetics Pharmaceuticals Inc, H1 2020
Acromegaly - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020
Acromegaly - Pipeline by Dauntless Pharmaceuticals Inc, H1 2020
Acromegaly - Pipeline by DexTech Medical AB, H1 2020
Acromegaly - Pipeline by Enesi Pharma Ltd, H1 2020
Acromegaly - Dormant Projects, H1 2020
Acromegaly - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Acromegaly, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Amryt Pharma Plc
Antisense Therapeutics Ltd
Aquestive Therapeutics Inc
Ascil Proyectos SL
Auritec Pharmaceuticals Inc
Camurus AB
Chiasma Inc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Dauntless Pharmaceuticals Inc
DexTech Medical AB
Enesi Pharma Ltd
Foresee Pharmaceuticals Co Ltd
GeneScience Pharmaceuticals Co Ltd
GlyTech Inc
GP Pharm SA
Ionis Pharmaceuticals Inc
Italfarmaco SpA
Midatech Pharma Plc
Ono Pharmaceutical Co Ltd
OPKO Health Inc
Strongbridge Biopharma plc